Teleflex (NYSE:TFX) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsBradley Bowers - VP of Equity ResearchJayson Bedford - Managing Director of Equity ResearchJohn Deren - EVP and CFOLawrence Keusch - Vice President of Investor Relations and Strategy DevelopmentStuart Randle - Interim President and CEOTravis Steed - Managing Director of Medical Technology Equity ResearchConference Call ParticipantsLarry Biegelsen - Senior Medical Device Equity Research AnalystMatthew O'Brien - Managi ...

Group 1 - On February 12, Jianda Zhixin's stock price fell by 1.37%, with a trading volume of 66.01 million yuan [1] - The financing data for Jianda Zhixin on the same day showed a financing purchase amount of 5.46 million yuan and a financing repayment of 10.02 million yuan, resulting in a net financing buy of -4.56 million yuan [1] - As of February 12, the total balance of margin trading for Jianda Zhixin was 92.45 million yuan, accounting for 6.39% of its circulating market value [1] Group 2 - As of December 31, Jianda Zhixin had 25,900 shareholders, a decrease of 10.35% from the previous period, while the average circulating shares per person increased by 11.55% to 1,949 shares [2] - For the period from January to September 2025, Jianda Zhixin reported an operating income of 14.861 billion yuan, representing a year-on-year growth of 10.18%, and a net profit attributable to shareholders of 230 million yuan, which is a 45.01% increase year-on-year [2]

Group 1 - The core viewpoint of the news is that Jianfa Zhixin experienced a slight decline in stock price and trading volume on February 6, with a net financing outflow reported [1] - On February 6, Jianfa Zhixin's financing buy amounted to 2.09 million yuan, while financing repayment was 3.29 million yuan, resulting in a net financing buy of -1.19 million yuan [1] - As of February 6, the total financing and securities balance for Jianfa Zhixin was 99.70 million yuan, accounting for 6.75% of its market capitalization [1] Group 2 - As of December 31, Jianfa Zhixin had 25,900 shareholders, a decrease of 10.35% compared to the previous period [2] - The average number of circulating shares per shareholder increased by 11.55% to 1,949 shares [2] - For the period from January to September 2025, Jianfa Zhixin reported operating revenue of 14.861 billion yuan, a year-on-year increase of 10.18%, and a net profit attributable to shareholders of 230 million yuan, reflecting a 45.01% year-on-year growth [2]

Group 1 - The core collaboration between the company and Koser Medical focuses on the distribution of vascular interventional products, with an expected annual distribution scale of approximately 100 million yuan [1] - The actual implementation of the distribution business in 2026 may be influenced by factors such as channel expansion, indicating a degree of uncertainty [1]

Core Viewpoint - The company has entered into a distribution partnership with Koseir Medical, focusing on vascular intervention products, with an expected annual distribution scale of approximately 100 million yuan [1] Group 1 - The collaboration with Koseir Medical primarily involves the distribution of vascular intervention products [1] - The anticipated annual distribution scale from this partnership is around 100 million yuan [1] - The actual implementation of the distribution in 2026 may be influenced by factors such as channel expansion, introducing a degree of uncertainty [1]

Group 1 - The core point of the news is that Jianfa Zhixin experienced a stock price increase of 3.11% on January 5, with a trading volume of 126 million yuan, despite a net financing outflow of 451.27 million yuan for the day [1][2] - On January 5, Jianfa Zhixin had a financing buy amount of 7.2758 million yuan, with a total financing balance of 106 million yuan, representing 6.98% of its market capitalization [2] - The company, established on August 30, 2010, specializes in medical device direct sales and distribution, providing centralized operation services for medical consumables to hospitals [2] Group 2 - Jianfa Zhixin's revenue for the period from January to September 2025 reached 14.861 billion yuan, reflecting a year-on-year growth of 10.18%, while the net profit attributable to shareholders was 230 million yuan, up 45.01% year-on-year [2] - As of December 19, the number of shareholders for Jianfa Zhixin was 28,900, a decrease of 4.56% from the previous period, with an average of 1,747 circulating shares per person, an increase of 4.78% [2]

Core Viewpoint - The company emphasizes that the centralized procurement policy for medical devices is beneficial for the long-term healthy development of the medical device industry in China, despite concerns about its impact on profitability and the need for diversification into new business areas [1]. Group 1: Industry Insights - The centralized procurement policy, which aims to save costs for the medical insurance fund and residents, has been in place since 2020, leading to a growth phase in the medical device industry [1]. - The company’s main products, high-value medical consumables, have undergone multiple rounds of centralized procurement, covering areas such as vascular intervention, surgical medical consumables, and IVD diagnostic products [1]. Group 2: Company Strategy - The company has strategically diversified its product offerings to mitigate revenue fluctuations from single products and has actively developed distribution for innovative medical devices [1]. - In response to the DRGS policy and the demand for lean management of hospital consumables, the company has also expanded into SPD management services [1]. - The management is focused on high-quality development and is strategically evaluating new business forms, digital technologies, and service areas for potential inclusion in the company's growth strategy [1].

Group 1 - The core viewpoint of the news is that Jianfa Zhixin has shown fluctuations in its stock performance and financing activities, with a slight increase in stock price and notable changes in financing and shareholder metrics [1][2]. Group 2 - On December 22, Jianfa Zhixin's stock price increased by 0.09%, with a trading volume of 153 million yuan. The financing data indicates a financing buy-in of 11.06 million yuan and a financing repayment of 12.49 million yuan, resulting in a net financing outflow of 1.42 million yuan [1]. - As of December 22, the total balance of margin trading for Jianfa Zhixin is 123 million yuan, which accounts for 7.53% of its market capitalization [1]. - The company has not engaged in any short selling activities on December 22, with no shares sold or repaid [1]. Group 3 - As of November 30, the number of shareholders for Jianfa Zhixin is 30,200, a decrease of 20.40% from the previous period. The average circulating shares per person increased by 25.63% to 1,667 shares [2]. - For the period from January to September 2025, Jianfa Zhixin reported a revenue of 14.861 billion yuan, representing a year-on-year growth of 10.18%. The net profit attributable to the parent company was 230 million yuan, showing a significant increase of 45.01% year-on-year [2].

Core Viewpoint - The company Jianfa Zhixin has shown a slight decline in stock price, with a trading volume of 327 million yuan and a net financing inflow of 1.69 million yuan on November 25, indicating ongoing investor interest despite the minor price drop [1]. Financing Summary - On November 25, Jianfa Zhixin had a financing buy-in amount of 27.29 million yuan, with a total financing balance of 96.47 million yuan, representing 5.81% of its market capitalization [1]. - The company reported no short-selling activity on the same day, with a short-selling balance of 0 yuan [1]. Business Performance - As of September 30, Jianfa Zhixin had 38,000 shareholders, an increase of 151.60% from the previous period, while the average number of circulating shares per shareholder decreased by 60.25% [2]. - For the period from January to September 2025, the company achieved a revenue of 14.861 billion yuan, reflecting a year-on-year growth of 10.18%, and a net profit attributable to shareholders of 230 million yuan, which is a 45.01% increase year-on-year [2]. Company Overview - Jianfa Zhixin Medical Technology Group Co., Ltd. was established on August 30, 2010, and is located in Yangpu District, Shanghai. The company specializes in the direct sales and distribution of medical devices and provides centralized operation services for medical consumables to hospitals [1]. - The main revenue sources for the company include vascular intervention (55.61%), surgical instruments (21.46%), in vitro diagnostic reagents (13.05%), medical equipment (6.24%), and other medical devices (2.79%) [1].

Investment Rating - The report maintains a "Strong Buy" rating for the company [4] Core Views - The company reported a revenue of 1.867 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 22.47%, with a net profit attributable to shareholders of 623 million yuan, up 18.02% year-on-year [1] - The third quarter revenue reached 654 million yuan, showing a year-on-year increase of 24.77%, while the net profit attributable to shareholders was 198 million yuan, growing 6.77% year-on-year [1] - The company is increasing its investment in the electrophysiology business, with expectations for rapid growth in PFA procedures and improvements in product offerings [7] - The market share in vascular intervention is steadily increasing, driven by new product iterations and a focus on enhancing existing product lines [7] - The gross margin remains stable, although profit growth in Q3 has slowed due to increased investments [7] - Revenue forecasts for 2025-2027 are adjusted to 2.561 billion, 3.339 billion, and 4.350 billion yuan, with corresponding net profits of 836 million, 1.057 billion, and 1.380 billion yuan, reflecting growth rates of 24%, 26%, and 31% respectively [7] Financial Data and Valuation - Total revenue for 2023 is projected at 1.650 billion yuan, with a year-on-year growth of 36% [3] - The company’s PE ratio is expected to decrease from 75.3 in 2023 to 29.1 by 2027, indicating improving valuation metrics [10] - The company’s ROE is projected to remain strong at around 29% over the forecast period [10] - The gross margin is expected to improve slightly from 71.3% in 2023 to 73.7% by 2027 [10] Stock Performance - The stock has shown a relative performance of -10% over the past month and a 24% increase over the past year [6]